OOncostellae — Seed (estimated) · €1.85M
This €1.85M capital increase was led by the founders of Palobiofarma (not a single named investor), with existing shareholder Inveready taking part and XesGalicia and Unirisco joining as new shareholders. It funds preclinical and clinical work in IBD, psoriasis and autoimmune disease, and solid tumours, including the first Phase I trial of OST-122. Crunchbase files it as a Series A of about $2.16M led by Inveready, which the company's own release does not support.
Lead unknown
RoundSeed (estimated)
Announced23 Jul 2017
CitySantiago de Compostela
SectorHealthtech & Bio · Biotech / Pharma
Source
O
O
